Background: Breast cancer is a leading cause of death among Iraqi women, necessitating studies on its demographic and clinical factors to guide diagnosis and treatment approaches. This study aimed to identify the demographic and clinical characteristics of a sample of Iraqi women with breast cancer and predictors of therapy receipt. Methods: A cross-sectional study was conducted in Karbala Province, Iraq, from October 2024 to February 2025 at the Al-Husseini Medical City Oncology Department. Data on age, marital status, employment, residence, menopausal status, family history, disease stage, treatment, and receptor involvement were collected. The χ2 test was used to compare the metastatic and nonmetastatic groups. Multinomial logistic regression was used to identify predictors of therapy receipt. Results: Of 1737 recorded cancer cases in Karbala Province, 342 (19.7%) were diagnosed as breast cancer. Among these, 152 cases (44.4%) met the inclusion criteria. Most cases were nonmetastatic (n = 123; 80.9%), estrogen receptor–positive, progesterone receptor–positive, and underwent surgery and chemotherapy. Family history (odds ratio [OR], 2.75; 95% CI, 1.00–7.54), stage I disease (OR, 4.05; 95% CI, 3.72–4.41), stage II disease (OR, 3.13; 95% CI, 1.91–5.12), stage III disease (OR, 3.56; 95% CI, 2.18–4.66), radiation therapy (OR, 0.02; 95% CI, 0.001–0.55), chemotherapy (OR, 0.15; 95% CI, 0.05–0.50), and targeted therapy (trastuzumab) (OR, 0.03; 95% CI, 0.01–0.18) were associated with hormonal therapy. Being menopausal (OR, 0.08; 95% CI, 0.01–0.60), having human epidermal growth factor receptor 2 (HER2)–positive status (OR, 5.34; 95% CI, 1.51–18.89), and receiving hormonal therapy (OR, 0.02; 95% CI, 0.002–0.18) were associated with targeted therapy (trastuzumab). Conclusion: The findings of this study show that breast cancer treatment decisions—especially for hormonal and targeted therapies—are linked to clinical factors such as hormone receptor status, HER2 involvement, disease stage, and menopausal status.